Friday, 9 October 2026European Markets

AHOLD DEL And CARREFOUR Have A High Dividend Yield And Return On Equity In The Grocery Stores Industry.

Loading stream...

(vianews) - ahold del (ad.as) is among this list of stock assets with the highest dividend rate and return on equity on the grocery stores industry.

financial asset price forward dividend yield return on equity
ahold del (ad.as) €30.11 4.01% 17.48%
carrefour (ca.pa) €18.17 2.85% 12.51%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ahold del (ad.as)

4.01% forward dividend yield and 17.48% return on equity

koninklijke ahold delhaize n.v. operates retail food stores and e-commerce primarily in the united states and europe. its store formats include supermarkets, convenience stores, drugstores, and hypermarkets. the company was formerly known as koninklijke ahold n.v. and changed its name to koninklijke ahold delhaize n.v. in july 2016. koninklijke ahold delhaize n.v. was founded in 1887 and is headquartered in zaandam, the netherlands.

earnings per share

as for profitability, ahold del has a trailing twelve months eps of €2.53.

pe ratio

ahold del has a trailing twelve months price to earnings ratio of 11.9. meaning, the purchaser of the share is investing €11.9 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.48%.

volatility

ahold del's last week, last month's, and last quarter's current intraday variation average was 0.09%, 0.45%, and 0.90%.

ahold del's highest amplitude of average volatility was 0.41% (last week), 1.25% (last month), and 0.90% (last quarter).

more news about ahold del.

2. carrefour (ca.pa)

2.85% forward dividend yield and 12.51% return on equity

carrefour sa operates stores in various formats and channels in france, spain, italy, belgium, poland, romania, brazil, argentina, and taiwan. the company operates hypermarkets, supermarkets, convenience stores, cash and carry stores, and hypercash stores; e-commerce sites; and service stations. its stores offer fresh produce; local products; consumer goods; and non-food products, including electronic and household appliances, textiles, and childcare products. the company is also involved in banking, insurance, property development, and franchise activities; the provision of travel agency services; and the rental of shopping malls. carrefour sa was founded in 1959 and is based in massy, france.

earnings per share

as for profitability, carrefour has a trailing twelve months eps of €1.32.

pe ratio

carrefour has a trailing twelve months price to earnings ratio of 13.77. meaning, the purchaser of the share is investing €13.77 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.51%.

volatility

carrefour's last week, last month's, and last quarter's current intraday variation average was 0.03%, 0.47%, and 1.32%.

carrefour's highest amplitude of average volatility was 0.28% (last week), 1.54% (last month), and 1.32% (last quarter).

moving average

carrefour's worth is higher than its 50-day moving average of €16.86 and above its 200-day moving average of €16.71.

more news about carrefour.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com